To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female subjects aged at least 18 years at Visit 1.

2. A clinical diagnosis of stable (at least 6 months) psoriasis vulgaris involving 5% to 30% body surface area (BSA), not including the face, axilla and groin.

3. A PGA of disease severity of at least moderate disease severity (Grade ≥ 3).

4. A plaque elevation of at least moderate severity (Grade ≥ 3) at the target lesionsite. The most severe lesion at baseline should be identified as the target lesion.

5. Provide written informed consent. -

Exclusion Criteria:

1. Current diagnosis of unstable forms of psoriasis in the treatment area includingguttate, erythrodermic, exfoliative, or pustular psoriasis.

2. Other inflammatory skin disease in the treatment area that may confound the evaluationof the psoriasis vulgaris (e.g., atopic dermatitis, contact dermatitis, tineacorporis).

3. Presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in thetreatment areas that could interfere with the rating of efficacy parameters.

4. History of psoriasis unresponsive to topical treatments.

5. History of hypersensitivity to any component of the Test or Reference product.

6. Current or past history of hypercalcemia, calcium metabolism disorder, vitamin Dtoxicity, severe renal insufficiency, or severe hepatic disorders.

7. Current immunosuppression.

8. Use within 6 months prior to baseline of biologic treatment for psoriasis (e.g.,infliximab, adalimumab, alefacept).

9. Use within 3 months prior to baseline of: 1) chemotherapy or 2) radiation therapy.

10. Use within 2 months prior to baseline of: 1) immunosuppressive drugs (e.g.,tacrolimus, pimecrolimus) or 2) oral retinoids.

11. Use within 1 month prior to baseline of: 1) systemic steroids, 2) systemicantibiotics, 3) other systemic antipsoriatic treatment, 4) psoralen and ultraviolet A (PUVA) therapy, 5) ultraviolet B (UVB) therapy, or 6) systemic anti-inflammatoryagents. Note: a) Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin use on anas-needed basis and if not used consecutively for > 14 days prior to baseline and/orduring the study is acceptable. Low-dose (81 mg) aspirin taken daily is acceptable. b)Intranasal or inhaled corticosteroids are acceptable if kept constant throughout thestudy. Intra-articular steroid injections are permissible.

12. Use within 2 weeks prior to baseline of: 1) topical antipsoriatic drugs (e.g.,salicylic acid, anthralin, coal tar, calcipotriene, tazarotene), 2) topicalcorticosteroids, or 3) topical retinoids.

13. Use within 2 weeks prior to baseline of: 1) vitamin D supplements 2) vitamin D analogsat a dose >400 IU/day; or 3) calcium supplements (including multivitamins containingcalcium).

14. Started beta-blocker therapy, antimalarial products, and/or lithium within 3 months ofbaseline. Subjects who have been on a steady dose for at least 3 months prior tobaseline and will remain on the same dose throughout the study are eligible for studyparticipation.

15. Subjects with planned phototherapy and/or exposure to ultraviolet A (UVA) and/or UVBduring the study.